Zevra Therapeutics
ZVRA
109 hedge funds and large institutions have $283M invested in Zevra Therapeutics in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 18 reducing their positions, and 23 closing their positions.
634% more call options, than puts
Call options by funds: $3.95M | Put options by funds: $539K
133% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 18
41% more capital invested
Capital invested by funds: $201M → $283M (+$81.9M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
8.53% more ownership
Funds ownership: 55.03% → 63.56% (+8.5%)
9% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 23
1% more funds holding
Funds holding: 108 → 109 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$25.6M |
| 2 |
BlackRock
New York
|
+$8.18M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$6.73M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$5.09M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$4.98M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$3.64M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$2.68M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.43M |
| 5 |
Jane Street
New York
|
-$1.31M |
ZVRA Hedge Fund Activity: Q4 2024 in Review
109 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q4 2024, worth a combined $283M — up 41% from $201M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ZVRA positions and 23 closed out — a net gain of 2 holders — while 42 added to existing stakes and 18 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $25.6M. The largest seller was Nantahala Capital Management, cutting an estimated $4.98M.
- 109 institutional investors held Zevra Therapeutics (ZVRA) as of Q4 2024, up from 108 in Q3 2024.
- Funds reported $283M of Zevra Therapeutics stock for Q4 2024, up 41% quarter-over-quarter.
- 25 funds opened new Zevra Therapeutics positions in Q4 2024 and 23 closed out, a net change of +2 holders.
- The largest Zevra Therapeutics buyer in Q4 2024 was Adage Capital Partners, an estimated $25.6M added.
- The largest Zevra Therapeutics seller in Q4 2024 was Nantahala Capital Management, an estimated $4.98M sold.
Based on aggregated 13F filings for Q4 2024.